Toxicity profile characteristics of novel androgen-deprivation therapy agents in patients with prostate cancer: a meta-analysis-Reference-Cited by-同舟云学术

Toxicity profile characteristics of novel androgen-deprivation therapy agents in patients with prostate cancer: a meta-analysis

Published:2017-12-26 Issue:2 Volume:18 Page:193-198
ISSN:1473-7140
Container-title:Expert Review of Anticancer Therapy
language:en
Short-container-title:Expert Review of Anticancer Therapy

Author:

Zhu Jianhong¹²,Liao Rifang¹²,Su Chen¹²,Liang Dan¹²,Wu Junyan¹²,Qiu Kaifeng¹²,Li Jianfang¹²

Affiliation:

1. Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, PR China

2. Department of pharmacy, Sun-Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, PR China

Funder

Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher Education Institutes

Key Laboratory of Malignant Tumor Molecular Mechanism and Translational Medicine of Guangzhou Bureau of Science and Information Technology

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737140.2018.1419871

Reference31 articles.

1. Increasing incidence of metastatic prostate cancer in the United States (2004–2013)

2. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial

3. Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials

4. Enzalutamide for the treatment of metastatic castration-resistant prostate cancer

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapy resistance in prostate cancer: mechanism, signaling and reversal strategies;Exploration of Targeted Anti-tumor Therapy;2024-08-29

2. Abiraterone or Enzalutamide for Patients With Metastatic Castration-Resistant Prostate Cancer;JAMA Network Open;2024-08-16

3. Comprehensive Review on Recent Strategies for Management of Prostate Cancer: Therapeutic Targets and SAR;Mini-Reviews in Medicinal Chemistry;2024-04

4. Newly identified adverse events of enzalutamide using the food and drug administration adverse event reporting system;Expert Opinion on Drug Safety;2023-09-05

5. Hospitalizations Among Veterans Treated for Metastatic Prostate Cancer With Abiraterone or Enzalutamide;Clinical Genitourinary Cancer;2023-07